FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104 Estimated average burden

hours per response: 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

2. Date of Event Requiring Statement (Month/Day/Year) 10/28/2021		3. Issuer Name and Ticker or Trading Symbol Entrada Therapeutics, Inc. [TRDA]						
_		4. Relationship of Report Issuer (Check all applicable) Director Officer (give title below)		10% O	wner (specify	File 6. Ir	d (Month/Day/ ndividual or Jo eck Applicable Form filed I	Year) int/Group Filing
_						X	Person Form filed I Reporting I	by More than One Person
(City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned								
				Form: D (D) or Ir	Direct ndirect			
)		
2. Date Exercisable and Expiration Date (Month/Day/Year)		Underlying Derivative Security Conve or Exe		Conver or Exer	cise Form:		6. Nature of Indirect Beneficial Ownership (Instr.	
ate xercisable	Expiration Date	Title	Nur	mber of	Derivative Security		or Indirect (I) (Instr. 5)	5)
(1)	(1)	Common Stock	3,8	16,760	0.00	(1)	I	See Footnote ⁽²⁾⁽³⁾
(1)	(1)	Common Stock	50	09,024	0.00	(1)	I	See Footnote ⁽²⁾⁽⁴⁾
	Table II - No. Table II - No. Date Exercision Dayly ate xercisable (1)	Table II - Derivative III - Derivative III - Derivative III - Derivative III - Date Exercisable and Expiration Date Month/Day/Year) ate Expiration Date III - Derivative III -	Requiring Statement (Month/Day/Year) 10/28/2021 4. Relationship of Reportsure (Check all applicable) Director Officer (give title below) 2. Amount of Securities Beneficially Owned (Inst. 4) Table II - Derivative Securities Beneficially Owned (Inst. 4) Table II - Derivative Securities Beneficially Owned (Inst. 4) Table Exercisable and Amount of Securities Date (Instr. 4) Title Expiration Date (Instr. 4) Title (I) (I) Common Stock	Requiring Statement (Month/Day/Year) 10/28/2021 4. Relationship of Reporting Issuer (Check all applicable) Director X Officer (give title below) 2. Amount of Securities Beneficially Owned (Instr. 4) Table II - Derivative Securities Beneficially, puts, calls, warrants, options, convertil (Instr. 4) Date Exercisable and xpiration Date (Instr. 4) 3. Title and Amount of Securities Date (Instr. 4) Title Minimal Amount of Securities Securities Date (Instr. 4) Title (Instr. 4) Amount of Securities Beneficial (Instr. 4) Title (Instr. 4) Amount of Securities Beneficial (Instr. 4) Title (Instr. 4) Amount of Securities Beneficial (Instr. 4) Title (Instr. 4) Amount of Securities Beneficial (Instr. 4) Title (Instr. 4) Amount of Securities Beneficial (Instr. 4) Title (Instr. 4) Amount of Securities Beneficial (Instr. 4) Title (Instr. 4)	Requiring Statement (Month/Day/Year) 10/28/2021 4. Relationship of Reporting Person(state and policable) Director X 10% Officer (give title below) 2. Amount of Securities Beneficially Owned (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) Table II - Derivative Securities Beneficially Owned (Instr. 4) Table II - Derivative Securities Beneficially Owned (Instr. 4) Table II - Derivative Securities Beneficially Owned (Instr. 4) Table Exercisable and Amount of Securities Underlying Derivative Security (Instr. 4) Amount of Number of Shares Title (1) (1) Common Stock 3,816,760	Requiring Statement (Month/Day/Year) 10/28/2021 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below) 2. Amount of Securities Beneficially Owned (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) Table II - Derivative Securities Beneficially Owned (Instr. 5) Table II - Derivative Securities Beneficially Owned (Instr. 5) Table Exercisable and Application Date (Instr. 4) 3. Title and Amount of Securities Securities (Instr. 4) Amount or Number of Shares Amount or Number of Shares (I) (I) Common Stock 3,816,760 0.00	Requiring Statement (Month/Day/Year) 10/28/2021 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below) 2. Amount of Securities Beneficially Owned (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 5) Table II - Derivative Securities Beneficially Owned (Instr. 5) Table II - Derivative Securities Beneficially Owned (Instr. 5) Table Exercisable and Axpiration Date (Instr. 4) Date Exercisable and Axpiration Date (Instr. 4) Amount of Securities Beneficially Owned (Instr. 4) Amount of Securities Beneficially Owned (Instr. 4) Amount of Securities Securities (I) (Instr. 5) Amount of Securities Securities (I) (Instr. 5) Amount of Securities (I) (Instr. 5) Amount of Number of Shares (I)	Requiring Statement (Month/Day/Year) 10/28/2021 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below) Officer (give title below) Director X 10% Owner Other (specify below) Able I - Non-Derivative Securities Beneficially Owned 2. Amount of Securities Beneficially Owned (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) Table II - Derivative Securities Beneficially Owned (Instr. 5) Table II - Derivative Securities Beneficially Owned (Instr. 4) Table II - Derivative Securities Beneficially Owned (Instr. 4) Table II - Derivative Securities Beneficially Owned (Instr. 4) Table II - Derivative Securities Beneficially Owned (Instr. 4) Table II - Derivative Securities Beneficially Owned (Instr. 4) Table Exercisable and (Instr. 4) Amount or Number of Securities Price of Derivative Security (Instr. 4) Amount or Number of Security Security (Instr. 5) Title Common Stock 3,816,760 0.00(1) I

(Last)	(First)	(Middle)			
C/O MPM CAP					
450 KENDALL STREET					
(Street)					
CAMBRIDGE	MA	01242			
(City)	(State)	(Zip)			
1. Name and Addre		Person*			
EVNIN LUK (Last)		Person* (Middle)			
EVNIN LUK	(First)				
EVNIN LUK (Last)	(First)				
(Last) C/O MPM CAP	(First)				
(Last) C/O MPM CAP 450 KENDALL	(First) ITAL STREET				

(Last) C/O MPM CAP		(Middle)		
450 KENDALL	STREET			
(Street) CAMBRIDGE	MA	01242		
(City)	(State)	(Zip)		
1. Name and Address of Reporting Person* MPM BioVentures 2014 (B), L.P.				
(Last) C/O MPM CAP 450 KENDALL		(Middle)		
(Street) CAMBRIDGE	MA	01242		
(City)	(State)	(Zip)		
1. Name and Address MPM Asset I BV2014 LLC	<u>Management</u>			
(Last) C/O MPM CAP	(First) ITAL	(Middle)		
450 KENDALL	STREET			
(Street) CAMBRIDGE	MA	01242		
(City)	(State)	(Zip)		
Name and Address of Reporting Person* MPM BioVentures 2014 LLC				
(Last) C/O MPM CAP	(First)	(Middle)		
450 KENDALL	STREET			
(Street) CAMBRIDGE	MA	01242		
(City)	(State)	(Zip)		
1. Name and Addre				
(Last) C/O MPM CAP	(First)	(Middle)		
450 KENDALL	STREET			
(Street) CAMBRIDGE	MA	01242		
(City)	(State)	(Zip)		
1. Name and Address of Reporting Person* MPM BIOVENTURES 2018 (B), L.P.				

(Last)	(First)	(Middle)					
C/O MPM CAPITAL							
450 KENDALL STREET							
,							
(Street)							
CAMBRIDGE	MA	01242					
(City)	(State)	(Zip)					
1. Name and Address of Reporting Person*							
MPM ASSET MANAGEMENT							
INVESTORS BV2018 LLC							
(Last)	(First)	(Middle)					
C/O MPM CAPITAL							
450 KENDALL STREET							
(Street)		,					
CAMBRIDGE	MA	01242					
(City)	(State)	(Zip)					

Explanation of Responses:

- 1. Each share of Series A Preferred Stock and Series B Preferred Stock is convertible into shares of the Issuer's Common Stock on a 1:7.235890014 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock and Series B Preferred Stock will convert into shares of Common Stock of the Issuer. The Series A Preferred Stock and Series B Preferred Stock have no expiration dates.
- 2. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
- 3. The shares are held as follows: 1,733,129 by MPM BioVentures 2014, L.P. ("BV 2014"), 115,596 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 59,655 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 1,778,737 by MPM BioVentures 2018, L.P. ("BV 2018"), 94,538 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 35,105 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"), MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.
- 4. The shares are held as follows: 231,139 by BV 2014, 15,417 by BV 2014(B), 7,956 by AM BV2014 LLC, 237,222 by BV 2018, 12,608 by BV 2018(B) and 4,682 by AM BV2018 LLC.

Remarks:

See Form 4 for MPM BioVentures 2018, L.P for additional members of this joint filing.

/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM 10/28/2021 BioVentures 2014 GP LLC, the general partner of MPM BioVentures 2014, L.P. 10/28/2021 /s/ Luke Evnin /s/ Ansbert Gadicke 10/28/2021 /s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM 10/28/2021 BioVentures 2014 GP LLC, the general partner of MPM BioVentures 2014 (B), L.P. /s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 10/28/2021 LLC, the manager of MPM Asset Management Investors BV2014 LLC /s/ Ansbert Gadicke, managing director of 10/28/2021 MPM BioVentures 2014 LLC /s/ Ansbert Gadicke. 10/28/2021

managing director of
MPM BioVentures 2014
LLC, the managing
member of MPM
BioVentures 2014 GP LLC

/s/ Ansbert Gadicke, managing director of

MPM BioVentures 2018

LLC, the managing

member of MPM

BioVentures 2018 GP

LLC, the general partner of MPM BioVentures 2018

(B), L.P.

/s/ Ansbert Gadicke,

managing director of

MPM BioVentures 2018

LLC, the manager of

MPM Asset Management Investors BV2018 LLC

** Signature of Reporting

Date

10/28/2021

10/28/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.